<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00840411</url>
  </required_header>
  <id_info>
    <org_study_id>02197</org_study_id>
    <nct_id>NCT00840411</nct_id>
  </id_info>
  <brief_title>Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions</brief_title>
  <official_title>A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Extended Release Tablet Formulation of Clarithromycin (500 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Biaxin® XL Filmtab) in 66 Fasted, Healthy, Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the relative bioequivalence of a test
      clarithromycin extended release formulation to an equivalent oral dose of the commercially
      available extended release clarithromycin in a test population of 66 adult subjects under
      fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria

      Statistical Methods: FDA bioequivalence statistical methods
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Concentration</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Clarithromycin (test) First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Biaxin® XL (reference) First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin ER 500 mg tablets</intervention_name>
    <description>1 x 500 mg</description>
    <arm_group_label>Clarithromycin (test) First</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIAXIN® XL 500 mg tablets</intervention_name>
    <description>1 x 500 mg</description>
    <arm_group_label>Biaxin® XL (reference) First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Sex: Males or females who are surgically sterile or have been post-menopausal for at
             least 6 months; similar proportions of each preferred.

          -  Age: At least 18 years.

          -  Qualifying subjects must be in good health and physical condition as determined by
             medical history, complete physical examination, and laboratory tests, all obtained
             within four (4) weeks prior to study start. The subjects may not have a history of
             significant past illness expected to affect the investigation. The normal status of
             subjects will be confirmed by the following procedures:

               1. Laboratory Tests:

                  Hemoglobin, hematocrit, RBC, WBC, differential count, serum electrolytes (Nz, K,
                  Cl), fasting blood glucose, BUN, bilirubin,m creatinine, AST, ALT, LD, alkaline
                  phosphatase and urinalysis. HIV, Hepatitis B, Hepatitis C, and drugs of abuse
                  testing will be done for screening purposes only. Urine drugs of abuse testing
                  will be repeated at each check-in. Female subjects will have a serum pregnancy
                  test done at screening and a urine pregnancy test prior to each study period at
                  check-in. Post-menopausal females will have an FSH (Follicle Stimulating Hormone)
                  level performed to confirm post-menopausal status.

                  Laboratory values which are greater than ±20% of the normal range will not
                  qualify unless specifically accepted (with comment) by the Principal
                  Investigator. Results of HIV, Hepatitis B, Hepatitis C, and drugs of abuse must
                  be negative or non-reactive for the subject to qualify for the study.

               2. Electrocardiogram

        A 12-lead electrocardiogram (ECG) will be obtained for all subjects. The original tracings,
        plus interpretation, will be included in the case report form packet.

          -  Subjects must read and sign the Consent Form.

        Exclusion Criteria

          -  Subjects not complying with the above inclusion criteria must be excluded from the
             study.

          -  In addition, any one of the conditions listed below will exclude a subject from the
             study:

               1. History of treatment for alcoholism, substance abuse, or drug abuse within past
                  24 months.

               2. History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or
                  other serious illness.

               3. History of treatment for any gastrointestinal disorder within the past 5 years.

               4. History of treatment for asthma within the past five (5) years.

               5. History of diarrhea within 24 hours prior to dosing.

               6. Females who are pregnant or lactating.

               7. History of hypersensitivity to clarithromycin or any macrolide antibiotic.

        C. Conditions upon screening which might contraindicate or require that caution be used in
        the administration of dexmethylphenidate hydrochloride, including:

          1. Sitting systolic blood pressure below 90 mm Hg, or diastolic pressure below 50 mm Hg.

          2. Heart rate less than 50 beats per minute after a 5-minute rest in a seated position.

               -  Inability to read and/or sign the consent form.

               -  Treatment with any other investigational drug during the four (4) weeks prior to
                  the initial dosing for this study.

               -  Subjects who have donated blood within four (4) weeks prior to the initial dosing
                  for this study.

               -  Subjects who smoke or use tobacco products or are currently using nicotine
                  products (patches, gums, etc.). Three (3) consecutive months abstinence is
                  required.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Ziaee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gateway Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gateway Medical Research</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2009</study_first_posted>
  <results_first_submitted>June 18, 2009</results_first_submitted>
  <results_first_submitted_qc>June 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2009</results_first_posted>
  <last_update_submitted>September 1, 2009</last_update_submitted>
  <last_update_submitted_qc>September 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clarithromycin (Test) First</title>
          <description>Clarithromycin 500 mg ER Tablet (test) dosed in first period followed by Biaxin® XL 500 mg Filmtab® (reference) dosed in second period.</description>
        </group>
        <group group_id="P2">
          <title>Biaxin® XL (Reference) First</title>
          <description>Biaxin® XL 500 mg Filmtab® (reference) dosed in first period followed by Clarithromycin 500 mg ER Tablet (test) dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clarithromycin (Test) First</title>
          <description>Clarithromycin 500 mg ER Tablet (test) dosed in first period followed by Biaxin® XL 500 mg Filmtab® (reference) dosed in second period.</description>
        </group>
        <group group_id="B2">
          <title>Biaxin® XL (Reference) First</title>
          <description>Biaxin® XL 500 mg Filmtab® (reference) dosed in first period followed by Clarithromycin 500 mg ER Tablet (test) dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Concentration</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Clarithromycin</title>
            <description>Clarithromycin 500 mg ER Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Biaxin® XL</title>
            <description>Biaxin® XL 500 mg Filmtab® (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Concentration</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="640.08" spread="214.223"/>
                    <measurement group_id="O2" value="640.11" spread="231.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using PROC GLM procedures in SAS, analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>100.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>93.3</ci_lower_limit>
            <ci_upper_limit>107.1</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</title>
        <description>Bioequivalence based on AUC0-inf</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>AUCinf could not be estimated for some subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Clarithromycin</title>
            <description>Clarithromycin 500 mg ER Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Biaxin® XL</title>
            <description>Biaxin® XL 500 mg Filmtab® (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</title>
          <description>Bioequivalence based on AUC0-inf</description>
          <population>AUCinf could not be estimated for some subjects.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10255.3" spread="4102.34"/>
                    <measurement group_id="O2" value="11767.7" spread="5131.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using PROC GLM procedures in SAS, analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>86.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>80.1</ci_lower_limit>
            <ci_upper_limit>93.4</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration</title>
        <description>Bioequivalence based on AUC0-t</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Clarithromycin</title>
            <description>Clarithromycin 500 mg ER Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Biaxin® XL</title>
            <description>Biaxin® XL 500 mg Filmtab® (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration</title>
          <description>Bioequivalence based on AUC0-t</description>
          <population>Data from subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9735.5" spread="3813.66"/>
                    <measurement group_id="O2" value="11136.6" spread="4412.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using PROC GLM procedures in SAS, analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>87.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>81.0</ci_lower_limit>
            <ci_upper_limit>93.8</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

